Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $116 from $110 after the company reported positive Phase III Apollo data on patisiran in 225 hereditary ATTR amyloidosis with olyneuropathy patients. Importantly, patisiran demonstrated a clean safety profile that differentiates from Ionis Pharmaceuticals' (IONS) inotersen, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam. The stock in morning trading is up 41%, or $30.93, to $105.97. Ionis is down 8% to $54.10.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).